Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Predictors of loss to follow up among patients with type 2 diabetes mellitus attending a private not for profit urban diabetes clinic in Uganda - a descriptive retrospective study.

Tino S, Wekesa C, Kamacooko O, Makhoba A, Mwebaze R, Bengo S, Nabwato R, Kigongo A, Ddumba E, Mayanja BN, Kaleebu P, Newton R, Nyerinda M.

BMC Health Serv Res. 2019 Aug 23;19(1):598. doi: 10.1186/s12913-019-4415-4.

2.

Lack of effectiveness of adherence counselling in reversing virological failure among patients on long-term antiretroviral therapy in rural Uganda.

Birungi J, Cui Z, Okoboi S, Kapaata A, Munderi P, Mukajjanga C, Nanfuka M, Nyonyintono MS, Kim J, Zhu J, Kaleebu P, Moore DM.

HIV Med. 2019 Aug 21. doi: 10.1111/hiv.12790. [Epub ahead of print]

PMID:
31432614
3.

Internalizing Mental Disorders and Accelerated Cellular Aging Among Perinatally HIV-Infected Youth in Uganda.

Kalungi A, Womersley JS, Kinyanda E, Joloba ML, Ssembajjwe W, Nsubuga RN, Levin J, Kaleebu P, Kidd M, Seedat S, Hemmings SMJ.

Front Genet. 2019 Aug 2;10:705. doi: 10.3389/fgene.2019.00705. eCollection 2019.

4.

Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.

Namale G, Kamacooko O, Bagiire D, Mayanja Y, Abaasa A, Kilembe W, Price M, Ssemwanga D, Lunkuse S, Nanyonjo M, Ssenyonga W, Mayaud P, Newton R, Kaleebu P, Seeley J.

Sex Transm Infect. 2019 Sep;95(6):405-411. doi: 10.1136/sextrans-2018-053854. Epub 2019 Jul 2.

5.

Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.

Omooja J, Nannyonjo M, Sanyu G, Nabirye SE, Nassolo F, Lunkuse S, Kapaata A, Segujja F, Kateete DP, Ssebaggala E, Bbosa N, Aling E, Nsubuga RN, Kaleebu P, Ssemwanga D.

J Antimicrob Chemother. 2019 Oct 1;74(10):3021-3029. doi: 10.1093/jac/dkz261.

6.

Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age.

Inzaule SC, Jordan MR, Cournil A, Vitoria M, Ravasi G, Cham F, Le LV, Dzangare J, Hamunime N, Mutenda N, Aghokeng A, Bissek A, Billong S, Kaleebu P, Doherty M, Bertagnolio S.

AIDS. 2019 Sep 1;33(11):1797-1799. doi: 10.1097/QAD.0000000000002277.

PMID:
31149946
7.

Complimentary Methods for Multivariate Genome-Wide Association Study Identify New Susceptibility Genes for Blood Cell Traits.

Fatumo S, Carstensen T, Nashiru O, Gurdasani D, Sandhu M, Kaleebu P.

Front Genet. 2019 Apr 26;10:334. doi: 10.3389/fgene.2019.00334. eCollection 2019.

8.

Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and Schistosoma mansoni co-infected patients: a randomised controlled trial.

Abaasa A, Asiki G, Obuku Ekii A, Wanyenze J, Pala P, J van Dam G, Corstjens PLAM, Hughes P, Ding S, Pantaleo G, Kaleebu P, Elliott AM, Kamali A.

Version 2. Wellcome Open Res. 2019 Apr 3 [revised 2019 Jan 1];3:81. doi: 10.12688/wellcomeopenres.14683.2. eCollection 2018.

9.

Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.

Price MA, Rida W, Kilembe W, Karita E, Inambao M, Ruzagira E, Kamali A, Sanders EJ, Anzala O, Hunter E, Allen S, Edward VA, Wall KM, Tang J, Fast PE, Kaleebu P, Lakhi S, Mutua G, Bekker LG, Abu-Baker G, Tichacek A, Chetty P, Latka MH, Maenetje P, Makkan H, Kibengo F, Priddy F, Gilmour J.

J Infect Dis. 2019 Jul 2;220(3):432-441. doi: 10.1093/infdis/jiz127.

10.

Marburg virus disease outbreak in Kween District Uganda, 2017: Epidemiological and laboratory findings.

Nyakarahuka L, Shoemaker TR, Balinandi S, Chemos G, Kwesiga B, Mulei S, Kyondo J, Tumusiime A, Kofman A, Masiira B, Whitmer S, Brown S, Cannon D, Chiang CF, Graziano J, Morales-Betoulle M, Patel K, Zufan S, Komakech I, Natseri N, Chepkwurui PM, Lubwama B, Okiria J, Kayiwa J, Nkonwa IH, Eyu P, Nakiire L, Okarikod EC, Cheptoyek L, Wangila BE, Wanje M, Tusiime P, Bulage L, Mwebesa HG, Ario AR, Makumbi I, Nakinsige A, Muruta A, Nanyunja M, Homsy J, Zhu BP, Nelson L, Kaleebu P, Rollin PE, Nichol ST, Klena JD, Lutwama JJ.

PLoS Negl Trop Dis. 2019 Mar 18;13(3):e0007257. doi: 10.1371/journal.pntd.0007257. eCollection 2019 Mar.

11.

HIV subtype diversity worldwide.

Bbosa N, Kaleebu P, Ssemwanga D.

Curr Opin HIV AIDS. 2019 May;14(3):153-160. doi: 10.1097/COH.0000000000000534.

PMID:
30882484
12.

Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda.

Abaasa A, Nash S, Mayanja Y, Price M, Fast PE, Kamali A, Kaleebu P, Todd J.

Vaccine. 2019 Apr 3;37(15):2065-2072. doi: 10.1016/j.vaccine.2019.02.072. Epub 2019 Mar 8.

13.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.

Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, Anumendem D, Luhn K, Robinson C, Douoguih M, Watson-Jones D.

J Infect Dis. 2019 Jun 5;220(1):46-56. doi: 10.1093/infdis/jiz070.

14.

Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders' meeting held in Entebbe, Uganda.

Elliott AM, Roestenberg M, Wajja A, Opio C, Angumya F, Adriko M, Egesa M, Gitome S, Mfutso-Bengo J, Bejon P, Kapulu M, Seager Z, Lutalo T, Nazziwa WB, Muwumuza A, Yazdanbakhsh M, Kaleebu P, Kabatereine N, Tukahebwa E.

AAS Open Res. 2018 Apr 18;1:2. doi: 10.12688/aasopenres.12841.1.

15.

Phylogeography of HIV-1 suggests that Ugandan fishing communities are a sink for, not a source of, virus from general populations.

Bbosa N, Ssemwanga D, Nsubuga RN, Salazar-Gonzalez JF, Salazar MG, Nanyonjo M, Kuteesa M, Seeley J, Kiwanuka N, Bagaya BS, Yebra G, Leigh-Brown A, Kaleebu P.

Sci Rep. 2019 Jan 31;9(1):1051. doi: 10.1038/s41598-018-37458-x.

16.

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda.

Kitonsa J, Mayanja Y, Aling E, Kiwanuka J, Namutundu J, Anywaine Z, Ggayi AB, Kibengo F, Kiwanuka N, Kaleebu P.

PLoS One. 2019 Jan 30;14(1):e0210287. doi: 10.1371/journal.pone.0210287. eCollection 2019.

17.

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.

Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM.

Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018.

18.

Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.

Nakiboneka R, Mugaba S, Auma BO, Kintu C, Lindan C, Nanteza MB, Kaleebu P, Serwanga J.

Vaccine. 2019 Jan 3;37(1):113-122. doi: 10.1016/j.vaccine.2018.11.024. Epub 2018 Nov 17.

19.

Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.

Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC.

Hepatology. 2019 Apr;69(4):1426-1441. doi: 10.1002/hep.30342. Epub 2019 Mar 22.

20.

Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda.

Okoboi S, Castelnuovo B, Moore DM, Musaazi J, Kambugu A, Birungi J, Kaleebu P, Nanfuka M, Kamya MR, Van Rie A.

AIDS Res Ther. 2018 Oct 19;15(1):15. doi: 10.1186/s12981-018-0203-1.

21.

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.

Gossez M, Martin GE, Pace M, Ramjee G, Premraj A, Kaleebu P, Rees H, Inshaw J, Stöhr W, Meyerowitz J, Hopkins E, Jones M, Hurst J, Porter K, Babiker A, Fidler S, Frater J; SPARTAC Trial Investigators.

AIDS. 2019 Feb 1;33(2):185-197. doi: 10.1097/QAD.0000000000002044.

22.
23.

HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line.

Fily F, Ayikobua E, Ssemwanga D, Nicholas S, Kaleebu P, Delaugerre C, Pasquier E, Amoros Quiles I, Balkan S, Schramm B.

Trop Med Int Health. 2018 Oct;23(10):1075-1083. doi: 10.1111/tmi.13131.

24.

HIV treatment is associated with a two-fold higher probability of raised triglycerides: Pooled Analyses in 21 023 individuals in sub-Saharan Africa.

Ekoru K, Young EH, Dillon DG, Gurdasani D, Stehouwer N, Faurholt-Jepsen D, Levitt NS, Crowther NJ, Nyirenda M, Njelekela MA, Ramaiya K, Nyan O, Adewole OO, Anastos K, Compostella C, Dave JA, Fourie CM, Friis H, Kruger IM, Longenecker CT, Maher DP, Mutimura E, Ndhlovu CE, Praygod G, Pefura Yone EW, Pujades-Rodriguez M, Range N, Sani MU, Sanusi M, Schutte AE, Sliwa K, Tien PC, Vorster EH, Walsh C, Gareta D, Mashili F, Sobngwi E, Adebamowo C, Kamali A, Seeley J, Smeeth L, Pillay D, Motala AA, Kaleebu P, Sandhu MS.

Glob Health Epidemiol Genom. 2018;3. pii: e7. doi: 10.1017/gheg.2018.7. Epub 2018 May 8.

25.

CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA.

Martin GE, Pace M, Thornhill JP, Phetsouphanh C, Meyerowitz J, Gossez M, Brown H, Olejniczak N, Lwanga J, Ramjee G, Kaleebu P, Porter K, Willberg CB, Klenerman P, Nwokolo N, Fox J, Fidler S, Frater J.

Front Immunol. 2018 May 4;9:928. doi: 10.3389/fimmu.2018.00928. eCollection 2018.

26.

HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.

von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717.

27.

HIV seroprevalence, self-reported STIs and associated risk factors among men who have sex with men: a cross-sectional study in Rwanda, 2015.

Ntale RS, Rutayisire G, Mujyarugamba P, Shema E, Greatorex J, Frost SDW, Kaleebu P.

Sex Transm Infect. 2019 Feb;95(1):71-74. doi: 10.1136/sextrans-2017-053311. Epub 2018 Apr 21.

28.

Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection.

Ssemwanga D, Doria-Rose NA, Redd AD, Shiakolas AR, Longosz AF, Nsubuga RN, Mayanja BN, Asiki G, Seeley J, Kamali A, Ransier A, Darko S, Walker MP, Bruno D, Martens C, Douek D, Porcella SF, Quinn TC, Mascola JR, Kaleebu P.

J Infect Dis. 2018 Apr 23;217(10):1530-1534. doi: 10.1093/infdis/jiy071.

29.

Evaluation of HIV-1 rapid tests and identification of alternative testing algorithms for use in Uganda.

Kaleebu P, Kitandwe PK, Lutalo T, Kigozi A, Watera C, Nanteza MB, Hughes P, Musinguzi J, Opio A, Downing R, Mbidde EK.

BMC Infect Dis. 2018 Feb 27;18(1):93. doi: 10.1186/s12879-018-3001-4.

30.

HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.

Serwanga J, Ssemwanga D, Muganga M, Nakiboneka R, Nakubulwa S, Kiwuwa-Muyingo S, Morris L, Redd AD, Quinn TC, Kaleebu P; HIV Superinfection Study Group.

Vaccine. 2018 Jan 25;36(4):578-586. doi: 10.1016/j.vaccine.2017.11.075. Epub 2017 Dec 20.

PMID:
29274699
31.

Correction to: 'Test and Treat' Among Women at High Risk for HIV-Infection in Kampala, Uganda: Antiretroviral Therapy Initiation and Associated Factors.

Mayanja Y, Kamacooko O, Bagiire D, Namale G, Kaleebu P, Seeley J.

AIDS Behav. 2018 Mar;22(3):1062. doi: 10.1007/s10461-017-1998-9.

PMID:
29214411
32.

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.

Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Giron A, Hamers R, Inzaule S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S.

Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5. Erratum in: Lancet Infect Dis. 2017 Dec 15;:.

33.

'Test and Treat' Among Women at High Risk for HIV-infection in Kampala, Uganda: Antiretroviral Therapy Initiation and Associated Factors.

Mayanja Y, Kamacooko O, Bagiire D, Namale G, Kaleebu P, Seeley J.

AIDS Behav. 2018 Mar;22(3):1053-1061. doi: 10.1007/s10461-017-1973-5. Erratum in: AIDS Behav. 2017 Dec 6;:.

34.

Deriving an optimal threshold of waist circumference for detecting cardiometabolic risk in sub-Saharan Africa.

Ekoru K, Murphy GAV, Young EH, Delisle H, Jerome CS, Assah F, Longo-Mbenza B, Nzambi JPD, On'Kin JBK, Buntix F, Muyer MC, Christensen DL, Wesseh CS, Sabir A, Okafor C, Gezawa ID, Puepet F, Enang O, Raimi T, Ohwovoriole E, Oladapo OO, Bovet P, Mollentze W, Unwin N, Gray WK, Walker R, Agoudavi K, Siziya S, Chifamba J, Njelekela M, Fourie CM, Kruger S, Schutte AE, Walsh C, Gareta D, Kamali A, Seeley J, Norris SA, Crowther NJ, Pillay D, Kaleebu P, Motala AA, Sandhu MS.

Int J Obes (Lond). 2017 Oct 3. doi: 10.1038/ijo.2017.240. [Epub ahead of print]

35.

HIV-1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda: A phylogenetic and epidemiological approach.

Kiwuwa-Muyingo S, Nazziwa J, Ssemwanga D, Ilmonen P, Njai H, Ndembi N, Parry C, Kitandwe PK, Gershim A, Mpendo J, Neilsen L, Seeley J, Seppälä H, Lyagoba F, Kamali A, Kaleebu P.

PLoS One. 2017 Oct 12;12(10):e0185818. doi: 10.1371/journal.pone.0185818. eCollection 2017.

36.

Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry Analysis.

Jordan MR, Penazzato M, Cournil A, Vubil A, Jani I, Hunt G, Carmona S, Maphalala G, Mthethwa N, Watera C, Kaleebu P, Musanhu CC, Mtapuri-Zinyowera S, Dzangare J, Peeters M, Yang C, Parkin N, Bertagnolio S.

Clin Infect Dis. 2017 Nov 29;65(12):2018-2025. doi: 10.1093/cid/cix698.

PMID:
29020335
37.

A35 Viral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesis.

Hassan AS, Hare J, Kamini G, Yindom LM, Kamali A, Karita E, Kilemba W, Price MA, Borrow P, Bjorkman P, Albert J, Kaleebu P, Allan S, Fast P, Hunter E, Gilmour J, Ndung'u T, Rowland-Jones S, Sanders EJ, Esbjornsson J.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.034. doi: 10.1093/ve/vew036.034. eCollection 2017 Mar. No abstract available.

38.

Cardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy.

Kazooba P, Kasamba I, Mayanja BN, Lutaakome J, Namakoola I, Salome T, Kaleebu P, Munderi P.

Pan Afr Med J. 2017 May 15;27:40. doi: 10.11604/pamj.2017.27.40.9840. eCollection 2017.

39.

Association between serotonin transporter gene polymorphisms and increased suicidal risk among HIV positive patients in Uganda.

Kalungi A, Seedat S, Hemmings SMJ, van der Merwe L, Joloba ML, Nanteza A, Nakassujja N, Birabwa H, Serwanga J, Kaleebu P, Kinyanda E.

BMC Genet. 2017 Jul 25;18(1):71. doi: 10.1186/s12863-017-0538-y.

40.

HIV-1 full-genome phylogenetics of generalized epidemics in sub-Saharan Africa: impact of missing nucleotide characters in next-generation sequences.

Ratmann O, Wymant C, Colijn C, Danaviah S, Essex M, Frost SDW, Gall A, Gaiseitsiwe S, Grabowski M, Gray R, Guindon S, von Haeseler A, Kaleebu P, Kendall M, Kozlov A, Manasa J, Minh BQ, Moyo S, Novitsky V, Nsubuga R, Pillay S, Quinn TC, Serwadda D, Ssemwanga D, Stamatakis A, Trifinopoulos J, Wawer M, Leigh Brown A, de Oliveira T, Kellam P, Pillay D, Fraser C.

AIDS Res Hum Retroviruses. 2017 Nov;33(11):1083-1098. doi: 10.1089/AID.2017.0061. Epub 2017 May 25.

41.

COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.

Mayanja BN, Kasamba I, Levin J, Namakoola I, Kazooba P, Were J, Kaleebu P, Munderi P; CoLTART study team.

AIDS Res Ther. 2017 May 4;14:26. doi: 10.1186/s12981-017-0154-y. eCollection 2017.

42.

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.

Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H.

PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May.

43.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.

Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW.

EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.

44.

Hepatitis B serological markers and plasma DNA concentrations.

Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group.

AIDS. 2017 May 15;31(8):1109-1117. doi: 10.1097/QAD.0000000000001454.

45.

The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.

Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group.

BMC Infect Dis. 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3.

46.

Population attributable fraction of incident HIV infections associated with alcohol consumption in fishing communities around Lake Victoria, Uganda.

Kiwanuka N, Ssetaala A, Ssekandi I, Nalutaaya A, Kitandwe PK, Ssempiira J, Bagaya BS, Balyegisawa A, Kaleebu P, Hahn J, Lindan C, Sewankambo NK.

PLoS One. 2017 Feb 16;12(2):e0171200. doi: 10.1371/journal.pone.0171200. eCollection 2017.

47.

Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.

Goodall RL, Dunn DT, Nkurunziza P, Mugarura L, Pattery T, Munderi P, Kityo C, Gilks C, Kaleebu P, Pillay D, Gupta RK; DART Virology Group.

J Antimicrob Chemother. 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583.

48.

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.

Namakoola I, Kasamba I, Mayanja BN, Kazooba P, Lutaakome J, Lyagoba F, Kapaata AA, Kaleebu P, Munderi P; CoLTART study team.

BMC Res Notes. 2016 Dec 23;9(1):515. doi: 10.1186/s13104-016-2309-7.

49.

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.

Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK.

Lancet Infect Dis. 2017 Mar;17(3):296-304. doi: 10.1016/S1473-3099(16)30469-8. Epub 2016 Dec 1.

50.

The need for an integrated approach for chronic disease research and care in Africa.

Barr AL, Young EH, Smeeth L, Newton R, Seeley J, Ripullone K, Hird TR, Thornton JRM, Nyirenda MJ, Kapiga S, Adebamowo CA, Amoah AG, Wareham N, Rotimi CN, Levitt NS, Ramaiya K, Hennig BJ, Mbanya JC, Tollman S, Motala AA, Kaleebu P, Sandhu MS.

Glob Health Epidemiol Genom. 2016 Nov 29;1:e19. doi: 10.1017/gheg.2016.16. eCollection 2016.

Supplemental Content

Loading ...
Support Center